Alnylam (NASDAQ: ALNY) pre-announces 2025 revenue and unveils 2030 plan

Rhea-AI Filing Summary

Alnylam Pharmaceuticals reported preliminary 2025 global net product revenues of approximately 2,987 million, with about 995 million in the fourth quarter, from its approved RNAi therapies AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO. These figures are unaudited and may change when full results are released in February 2026.

The company also introduced a new five-year strategy called “Alnylam 2030,” outlined product and pipeline goals for 2026, and issued full-year 2026 combined net product revenue guidance, signaling how it plans to grow its commercial portfolio and advance its pipeline.

Insights

Biopharma equity analyst

Alnylam pre-announces strong 2025 product revenue and sets a new 2030 strategy with 2026 goals.

Alnylam reports preliminary 2025 global net product revenues of approximately 2,987 million, including about 995 million in Q4, from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO. These are unaudited figures, but they give an early view of the scale of the commercial portfolio ahead of the detailed release expected in February 2026.

The launch of the “Alnylam 2030” five-year strategy and disclosure of 2026 product and pipeline goals indicate a structured roadmap for both commercial expansion and R&D progress. The company also issued full-year 2026 combined net product revenue guidance, which will help frame expectations for revenue trajectory once the specific numbers are reviewed in the full results and strategy materials.

false0001178670January 11, 202600011786702026-01-112026-01-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2026

Alnylam Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

___________________________________________

Delaware			001-36407			77-0602661
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

675 West Kendall Street, Henri A. Termeer Square  Cambridge, Massachusetts			02142
(Address of Principal Executive Offices)			(Zip Code)

Registrant’s telephone number, including area code: (617) 551-8200

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, $0.01 par value per share

ALNY

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 11, 2026, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its new five-year strategy, “Alnylam 2030,” as well as its preliminary fourth quarter and full year 2025 global net product revenues of approximately $995 million and $2,987 million, respectively, for AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran), and provided the Company’s 2026 product and pipeline goals. The Company also announced full year 2026 combined net product revenue guidance.

The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results in February 2026.

The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

(d)     Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1     Press Release dated January 11, 2026.

104     Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 12, 2026			ALNYLAM PHARMACEUTICALS, INC.
			By:			/s/ Jeffrey V. Poulton
						Jeffrey V. Poulton
						Executive Vice President, Chief Financial Officer

FAQ

What preliminary 2025 revenues did Alnylam (ALNY) report in this 8-K?

Alnylam reported preliminary 2025 global net product revenues of approximately 2,987 million, including about 995 million in the fourth quarter, for AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO.

Which products contributed to Alnylam’s preliminary 2025 net product revenues?

The preliminary 2025 global net product revenues of approximately 2,987 million came from four products: AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran) and OXLUMO (lumasiran).

Are Alnylam’s preliminary Q4 and full-year 2025 revenues final?

No. Alnylam states these selected financial results are preliminary and unaudited, subject to adjustment, and provided as an approximation ahead of complete financial results expected in February 2026.

What is Alnylam’s new “Alnylam 2030” strategy mentioned in the filing?

Alnylam announced a new five-year strategy called “Alnylam 2030”, which accompanies its preliminary 2025 revenues and sets the company’s direction for its products and pipeline through the end of the decade.

Did Alnylam provide any goals or guidance for 2026 in this report?

Yes. Alnylam outlined its 2026 product and pipeline goals and announced full-year 2026 combined net product revenue guidance, giving an early view of its expectations for next year.

Where can investors find more detail on Alnylam’s 2025 results and 2030 strategy?

More detail is provided in the press release dated January 11, 2026 referenced as Exhibit 99.1, and the company plans to announce complete financial results in February 2026.